Vireo Growth (VREOF) Finished Goods (2020 - 2026)
Vireo Growth (VREOF) reported Finished Goods of $31.0 million for Q1 2026, up 385.11% on a YoY basis from $6.4 million in Q1 2025, and up 58.16% sequentially from $19.6 million in Q4 2025.
Vireo Growth (VREOF) Finished Goods (2020 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 7 years of Finished Goods data on file, last reported at $31.0 million in Q1 2026.
- For the quarter ending Q1 2026, Finished Goods rose 385.11% year-over-year to $31.0 million; the trailing twelve-month figure through Mar 2026 stood at $31.0 million (up 385.11% YoY), and the FY2025 full-year result was $19.6 million, up 230.34% from the prior year.
- Finished Goods advanced to $31.0 million in Q1 2026, from $19.6 million in the prior quarter.
- In the past five years, Finished Goods ranged from a high of $31.0 million in Q1 2026 to a low of $4.1 million in Q3 2022.
- A 5-year average of $9.3 million and a median of $5.8 million in 2024 frame the typical range for Finished Goods.
- Across the five-year window, Finished Goods declined 15.13% in 2022 and surged 385.11% in 2026, its largest moves.
- Tracing VREOF's Finished Goods over 5 years: stood at $5.5 million in 2022, then decreased by 4.15% to $5.3 million in 2023, then climbed by 12.41% to $5.9 million in 2024, then jumped by 230.34% to $19.6 million in 2025, then surged by 58.16% to $31.0 million in 2026.
- Business Quant data shows VREOF's Finished Goods at $31.0 million in Q1 2026, $19.6 million in Q4 2025, and $18.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 31.00 Mn |
| Dec 31, 2025 | 19.60 Mn |
| Sep 30, 2025 | 18.32 Mn |
| Jun 30, 2025 | 18.64 Mn |
| Mar 31, 2025 | 6.39 Mn |
| Dec 31, 2024 | 5.93 Mn |
| Sep 30, 2024 | 5.81 Mn |
| Jun 30, 2024 | 5.91 Mn |
| Mar 31, 2024 | 5.32 Mn |
| Dec 31, 2023 | 5.28 Mn |
| Sep 30, 2023 | 5.48 Mn |
| Jun 30, 2023 | 5.13 Mn |
| Mar 31, 2023 | 5.94 Mn |
| Dec 31, 2022 | 5.51 Mn |
| Sep 30, 2022 | 4.10 Mn |
| Jun 30, 2022 | 4.82 Mn |
| Mar 31, 2022 | 4.66 Mn |
| Dec 31, 2021 | 4.58 Mn |
| Sep 30, 2021 | 4.83 Mn |
| Jun 30, 2021 | 4.53 Mn |